<DOC>
	<DOCNO>NCT00323934</DOCNO>
	<brief_summary>In study , MGCD0103 , new anticancer drug investigation , give three time weekly patient advance solid tumor Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>Study MGCD0103 Given Three-Times Weekly Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patients must histologically cytologically document advanced metastatic solid malignancy aggressive NHL reasonable likelihood achieve clinical benefit exist therapy , fail respond standard therapy , progress despite standard therapy , standard therapy exists . Aggressive form NHL eligible study : Burkitt 's lymphoma Mantle cell lymphoma Diffuse large Bcell lymphoma Folliclecenter cell lymphoma , large cell Primary mediastinal large Bcell lymphoma Patients known central nervous system ( CNS ) metastases may enrol receive radiotherapy CNS disease , stable dose steroid least 1 month prior study entry , compute tomography ( CT ) magnetic resonance imaging ( MRI ) brain within 1 month study entry show stable disease free neurological symptom . Prior therapy allow : Cytotoxic therapy Hormonal therapy/other therapy Luteinizing hormone release hormone ( LHRH ) agonist therapy Radiation Surgery Adjuvant therapy Patients may unlimited prior adjuvant therapy . A minimum 28 day must pass since end last treatment study initiation . Patients must recover treatmentrelated toxicity . ECOG performance status 0 , 1 , 2 . Age â‰¥ 18 year . Minimum life expectancy least 3 month . Laboratory requirement Patients history another cancer basal cell carcinoma cervical intraepithelial neoplasia ( CIN/cervical situ ) unless previous cancer treat patient remain disease free five year prior current cancer diagnosis . Investigators desire enter patient second malignancy must discuss obtain write approval advance MethylGene Medical Monitor . Pregnant lactate woman . Women childbearing potential must negative serum pregnancy test document within 7 day prior registration study . Patients partner , either childbearing potential , use adequate birth control measure throughout course study . Both men woman enrol study must agree use medically acceptable effective form contraception study 90 day follow last dose study medication . An effective form contraception oral contraceptive double barrier method , condom diaphragm . Patients know meningeal metastasis ( es ) Patients active uncontrolled infection , fever &gt; 38.5 degree Celsius day schedule dose Patients serious illness , medical condition , medical history , include laboratory result , , investigator 's opinion , would likely interfere patient 's participation study , interpretation result Patients treated investigational drug within 30 day prior study initiation ( investigational drug one approve indication ) , receive concurrent treatment experimental drug anticancer therapy Known hypersensitivity histone deacetylase ( HDAC ) inhibitor component MGCD0103 Known HIV hepatitis B C ( active , prior treat , ) . Any condition ( e.g. , know suspected poor compliance , psychological instability , geographical location , etc ) , judgment investigator , may affect patient 's ability sign inform consent undergo study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>metastatic solid tumor</keyword>
	<keyword>aggressive non Hodgkin 's Lymphoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>